MGMT and glioblastoma: The effectiveness of PC was noted to be unsatisfactory, with a median OS from PC administration of 9.7 months (95% CI 6.7 to 12.7) and median PFS of 8 weeks, in a South Korean single-arm trial that enrolled eight patients with MGMT-methylated recurrent glioblastoma (181).